Keywords
Vaso occlusive pain
Treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To investigate the literature on the treatments available for vaso-occlusive crisis in patients with Sickle Cell Anemia. Methods: Integrative Literature Review. The electronic survey took place in the Pubmed and LILACS databases. The search in electronic databases took place with the help of the keywords “Sickle Cell Anemia”, “Treatment”, “Occlusive Vaso Pain”, “Sickle Cell Disease”. The words were further translated into English as follows: “Sickle cell anemia”, “Treatment”, “Vaso occlusive pain”, “Sickle cell disease”. Results: 16 studies were selected, the most recent being published in 2023 and the oldest in 2007. Acute pain occurs in regions of the back, chest, abdomen and extremities, and can be triggered by episodes of dehydration, infection, asthma attacks and very mild temperatures. The use of opioids in the treatment of vaso-occlusive pain crises in individuals with SCA can be considered effective. Final considerations: Hydroxyurea therapy is the only disease-modifying drug approved by the FDA and presents excellent results in terms of disease modification. Opioid drugs and non-steroidal anti-inflammatory drugs remain the basis for the treatment of patients with vaso-occlusive crisis.
References
AKINDELE AO, et al. Treatment Options that reduce the duration of sickle cell vaso-occlusive crises: A systematic Review. Cureus, 2022; 14 (8): 1-8.
BACHIR D, et al. Patterns of mortality in sickle cell disease in adults in France and England. Hematol J, 2002; 3 (1): 56-60.
BALLAS SK, et al. Hydroxyu; rea and acute painful crises in sickle cell anemia: effects in hospital length of stay and opioid utilization during hospitalization, outpatient acute care contats, and at home. J Pain Symptom Manage, 2010; 40 (6): 870-82.
BARTOLUCCI P, et al. A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. Blood, 2009; 114 (18): 3742-7.
BRANDOW AM, et al. Key componentes of pain management for children and adults with sickle cell disease. Hematol Oncol Clin North Am., 2018; 32 (3): 535-550.
CARDEN MA, et al. Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain. Am J Hematol., 2019; 94 (6): 686-696.
CARDOSO AIQ, et al. Estudos econômicos completos sobre tratamento da anemia falciforme. Acta Paul Enferm., 2021; 34: 1-7.
CARNEIRO KSC, et al. Avaliação de dor neuropática em pacientes com doença falciforme utilizando o instrumento Douleur Neuropathique 4 Questions (DN4). Monografia (Bacharel em Medicina) - Universidade Federal de Sergipe, Aracaju, 2019; 82 p.
EDWARDS LR, et al. National Institutes of health consensus development conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med., 2008; 148 (12): 932-8.
FEIN DM, et al. Intranasal fentanyl for initial treatment of vaso-occlusive crisis in sickle cell disease. Pediatr Blood Cancer., 2017; 64 (60): 1-7.
FRANCESCHI L, et al. Fentanyl Buccal tablet: a new breakthrough pain medication in early management of severe vaso occlusive crisis in sickle cell disease. Pain Pract., 2016; 16 (6): 680-7.
GLADWIN MT, et al. Sickle-cell disease. Lancet, 2010; 376 (97757): 2018-31.
GOLDMAN RD, et al. Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease. Pediatrics., 2013; 132 (6): 1634-41.
GRANJA PD, et al. Úlceras de perna em pacientes com anemia falciforme. J Vasc. Bras., 2020; 19: 1-8.
HOPPE C, et al. Simvastatin reduces vaso occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol., 2017; 177 (4): 620-629.
JESUS ACS, et al. Características socioeconômicas e nutricionais de crianças e adolescentes com anemia falciforme. Rev. Paul. Pediatr., 2018; 36 (4): 491-499.
KOYFMAN A, et al. Emergency medicine management of sickle cell disease complications: na evidence-based update. J emerg med., 2016; 51 (4): 370-81.
LUBEGA FA, et al. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial. Scand J Pain., 2018; 18 (1): 19-27.
MANFREDINI V, et al. A fisiopatologia da anemia falciforme. Informa, 2007; 19 (½): 1-4.
MOLOKIE RE, et al. Opioid doses and acute care utilization outcomes for adults with sickle cell disease: ED versus acute care unit. Am J Emerg Med., 2018; 36 (1): 88-92.
MORRIS CR, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica., 2013; 98 (9): 1375-82.
MORRIS CR, et al. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso occlusive pain. Blood., 2020; 136 (12): 1402-1406.
PURI L, et al. State of the art management of acute vaso-occlusive pain in sickle cell disease. Paediatr drugs,, 2018; 20(1): 29-42.
QARI MH, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double blind randomized trial. Thromb Haemost., 2007; 98 (2): 392-6.
ROLLÉ A, et al. Pain control for sickle cell crisis, a novel approach? A retrospective study. Medicina (Kaunas), 2023; 59 (12): 1-12.
ROUSSEAU V, et al. Efficacy and tolerance of lindocaine 5% patches in neuropathic pain and paint related to vaso occlusive sickle cell crises children: A prospective multicenter clinical study. Pain Pract, 2018; 18 (6): 788-797.
SOUSA GHM, et al. Anemia Falciforme. Revista Ibero-Americana de Humanidades, Ciências e Educação, 2021; 7 (11): 1-15.
TANABE P, et al. A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD). Am J Hematol., 2018; 93 (2): 159-168.
TELFER P, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol., 2003; 120 (5): 744-52.
TSHILOLO L, et al. Hydroxyurea for children with sickle cell anemia in sub saharan africa. N Engl J Med., 2019; 380 (2): 121-131.
WEINER DL, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA, 2003; 289 (9): 1136-42.